Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Dose Escalation Trial of Weekly Intravenous Administrations of BI 836845 in Patients With Advanced Solid Cancers With Repeated Administrations in Patients Showing Clinical Benefit

NCT01403974 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT01403974
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01403974 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Dose Escalation Trial of Weekly Intravenous Administrations of BI 836845 in Patients With Advanced Solid Cancers With Repeated Administrations in Patients Showing Clinical Benefit
Lead sponsor
Boehringer Ingelheim
Phase
Phase 1
Overall status
Completed
Start date
July 19, 2011
Completion date
December 23, 2015
Enrollment
61 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasms